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MPO bioavailability in patients with
severe heart failure
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1Stanford University, Division of CardiovascularMedicine, Stanford, CA, USA, 2University of Groningen, UniversityMedical Center
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Center Oldenburg, Department of Cardiology, Oldenburg, Germany, 4University of Hamburg, Heart Center, Department of
Cardiovascular Medicine, Hamburg, Germany, 5University of Cologne, Heart Center, Department of Cardiology and Cologne
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Treatment of decompensated heart failure often includes administration of levosimendan.Myeloperoxidase
(MPO) is released during polymorphonuclear neutrophil (PMN) degranulation, and mediates
dysregulation of vascular tone in heart failure.We evaluated the effects of levosimendan-treatment onMPO
in patients with acute decompensation of chronic heart failure over a one week course. Plasma MPO levels
were significantly decreased after levosimendan treatment (from 252.16 31.1 pmol/l at baseline to 215.02
6 27.96 pmol/l at 6 h, p , 0.05). Ex vivo incubation of whole blood with levosimendan decreased MPO
release after PMN-stimulation (8.2 6 1.4-fold increase at baseline vs. 6.0 6 1.1-fold increase with
levosimendan). MPO levels also significantly correlated with diastolic blood pressure over the time course.
In a multivariate linear model, the main contributor to systolic, diastolic and mean blood pressure was level
of PMN elastase. MPO contributed only in heparin-treated patients, suggesting a more significant role for
endothelial-boundMPO than for circulatingMPO or elastase with respect to blood pressure regulation.We
here provide the first evidence that levosimendan treatment inhibits MPO release by PMNs in
decompensated heart failure patients. This mechanismmay regulate endothelial function and vascular tone
in heart failure patients.
H eart failure (HF) is a significant cause of morbidity in Western society, affecting approximately 1–2% ofthe adult population. The prevalence is considered to be 8.4% for patients older than 75 years, whereas therisk of developing new onset heart failure is 0.2/1000 person-years in those aged 45–55 years, and increases
up to 12.4/1000 person-years for those over age 85. Five year mortality is high, ranging from 45% in women up to
59% in men, and accounting for 55,000 annual deaths in the US alone1–3.
Themajority of patients hospitalized for acute heart failure haveworsening chronic heart failure, rather than de
novo symptoms. Published data provide evidence for polymorphonuclear neutrophils (PMN) activation and
myeloperoxidase (MPO)-release in patients with severe HF4–6, with higher MPO levels found in patients with
more aggressive disease.MPO is a redox-activated hemoprotein, and is abundant in PMNs.WhileMPO ismainly
stored inside azurophilic granules of PMNs, it is also expressed inmonocytes and tissue-associated macrophages.
Upon secretion, it accumulates along the endothelium and in the subendothelial space. Beyond MPO’s bacter-
icidal properties, its role as a mediator and contributor in vascular inflammatory processes involved in coronary
artery disease andHF has been recently appreciated7–9. Endothelial nitric oxide (NO) bioavailability is reduced by
active MPO8, and outcomes in HF patients are adversely affected by decreased endothelial NO bioavailability10,11.
Moreover, vascular tone is profoundly altered by MPO12, and dysregulation of vascular tone and afterload in
patients are major pathobiological features in HF13–15.
For patients showing clinical signs of acute peripheral hypoperfusion due to HF, the current European Society
of Cardiology guidelines suggest levosimendan as a viable treatment option to help reverse the negative inotropic
effects of pre-existing oral beta-blocker treatment. Levosimendan, is a calcium sensitizer and opens K1-channels,
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but also has complex pleiotropic effects16. It has been shown that
levosimendan not only increases cardiac output17 but also may
improve endothelial function18 and suppress lipid peroxidation, pro-
tein oxidation and nitrosative stress19.
The present study assessed the effects of levosimendan on PMN
function and activation by analysis of MPO and elastase levels as
indicators of neutrophil degranulation in patients with acute heart
failure. Further, we analyzed the correlation of PMN activation with
blood pressure regulation and vascular tone in these patients.
Methods
Study outline. Twenty-five consecutive acute heart failure patients admitted to the
Department of General and Interventional Cardiology at the University Heart Center
Hamburg were enrolled. Patients referred to the unit with signs of acute heart failure
were evaluated for cardiac function and signs of acute peripheral hypoperfusion as
well as for co-morbidities and other potential causes for acute decompensation. All
patients underwent transthoracic echocardiography to verify low cardiac output,
defined as left ventricular ejection fraction below 30% (Simpson method). Patient
inclusion criteria consisted of: age.17 years, heart failure NYHA class III and IV, or
ACC/AHA class D, acute worsening of heart failure with signs of peripheral
hypoperfusion, clinical indication for treatment with levosimendan (not determined
by an study investigator), left ventricular ejection fraction below 30% determined by
echocardiography or cardiac MRI). Exclusion criteria comprised: severe impairment
of renal function (creatinine clearance ,30 ml/min), severe hepatic dysfunction
(bilirubin .2.0 mg/dl), systemic inflammatory disorders, overt infection,
malignancy, autoimmune disorders, and concomitant treatment with intravenous
vasoactive agents, such as inotropes or catecholamines.
Mean arterial pressure was calculated as diastolic blood pressure plus 1/3 of pulse
pressure (the difference between systolic and diastolic blood pressure). Right heart
catheterization was performed if indicated per standard-of-care (to verify diagnosis
or plan further treatment) within 24 hours before levosimendan treatment (twelve
out of twenty-five patients).
The study was performed in accordance with the Declaration of Helsinki and
approved by the Board of Physicians Ethics Committee Hamburg. All patients pro-
vided informed consent.
Levosimendan treatment. Levosimendan solution (0.025 mg/ml) was prepared
using a 5 ml vial containing 12.5 mg of levosimendan concentrate (Orion Oyj
Pharma, Finland) diluted in 500 ml sterile 5% glucose (B. Braun, Germany).
Administration was performed via a central venous line at a constant rate of 21 ml/
hour over 24 hours with no loading dose. If during administration a clinically
relevant decrease in blood pressure occurred, as judged by the treating physician, the
infusion was temporarily halted for a maximum of 1 hour, and then re-started at a
50% decreased rate.
Blood sample collection. Blood was collected at baseline (immediately before
levosimendan administration) and at 1, 6, 24, and 48 hours, as well as 1 week after
treatment initiation. Blood samples were processed immediately, and 2 ml of
separated plasma were pelleted and stored at 280uC pending further processing.
Laboratory measurements. MPO was quantitated using the CardioMPO kit
(Cleveland Heart Lab) according to manufacturer’s instructions. Elastase
immunoassay was performed using a PMN-Elastase ELISA kit (IBL International).
Plasma nitrite was analyzed using a Nitrate/Nitrite Fluorometric Assay Kit (Cayman
chemicals) without performing nitrate reduction.
Additionally, the following biomarkers were measured in plasma: C-reactive
protein (CRP; nephelometric immunoassay, Siemens for high sensitive CRP),
Table 1 | Patient characteristics
Characteristic Number Percentage
Gender (male vs. Female) 22/3 88%
Etiology (ischemic vs. Non ischemic) 7/18 28%
Number of patients at timepoint 0 h 25 100%
Number of patients at timepoint 1 h 25 100%
Number of patients at timepoint 6 h 25 100%
Number of patients at timepoint 24 h 25 100%
Number of patients at timepoint 48 h 19 76%
Number of patients at timepoint 168 h 18 72%
Mortality 0 0%
age (years) 58.4 6 2.6
BMI (kg/m2) 27.7 6 4.7
Presence of edema 13 52%
Dyspnea NYHA III 11 44%
Dyspnea NYHA IV 14 56%
Ejection fraction (Echocardiography) ,30% 25 100%
ACE-inhibitors/ARBs 18 72%
Beta-blockers 19 76%
Diuretics 20 80%
Digoxins 2 8%
Heparins 13 52%
Cumarins 11 44%
Statins 9 36%
Heart rate at rest (bpm) 76 6 6
Systolic blood pressure at rest (mmHg) 103 6 8
Diastolic blood pressure at rest (mmHg) 68 6 5
Aspartate aminotransferase (U/l) 48.1 6 10.7
Alanine aminotransferase (U/l) 61.6 6 16.4
Gamma – glutamyl transferase (U/l) 136.1 6 24.2
Total bilirubine (mg/dl) 1.0 6 0.2
Creatinine mg/dl (mg/dl) 1.5 6 0.1
C-reactive protein (mg/dl) 5.9 6 6.1
RAP - mean (mmHg) 9.4 6 3.5
RVP - systolic (mmHg) 45.9 6 9.6
RVP - diastolic(mmHg) 8.3 6 2.9
PAP - systolic (mmHg) 45.8 6 9.6
PAP - diastolic (mmHg) 21.5 6 4
PAP - mean (mmHg) 30.8 6 5.7
PCWP - mean (mmHg) 20.3 6 3.9
Cardiac index (l/min/m2) 1.9 6 0.6
BMI 5 body mass index, RAP 5 right atrial pressure, RVP 5 right ventricular pressure, PAP 5 pulmonary artery pressure, PCWP 5 pulmonary capillary wedge pressure.
www.nature.com/scientificreports
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Figure 1 | Effects of levosimendan on neutrophilic markers and markers of NO-production in plasma. Assessment of plasma markers at each specific
time point after levosimendan application (hours) for (A)MPO-concentration, (B) elastase-concentration and (C) nitrite-concentration. Data displayed
are for all available 25 patients (0–24 hours), 19 patients (48 hours) and 18 patients (168 hours). *5 p# 0.05, **5p# 0.01 versus timepoint 0 hours.
Level of significance was determined using a mixed linear model with posthoc LSD test.
Table 2 | Association analysis of blood pressure and inflammatory markers, all patients
A) Correlation analysis – coefficients of correlation shown
MPO Elastase Leukocyte count Granulocyte count Interleukin-6 Systolic/diastolic BP
BP systolic 0.089 (n.s.) 0.293** 0.245** 20.111 (n.s.) 0.155 (n.s.) 0.611**
BP diastolic 0.179* 0.402** 0.076 (n.s.) 20.153 (n.s.) 20.026 (n.s.) 0.611**
BP mean 0.167 (p 5 0.06) 0.393** 0.172* 20.156 (n.s) 0.019 (n.s) 0.866**/0.931**
CRP
BP systolic 20.068 (n.s.)
BP diastolic 20.034 (n.s.)
BP mean 20.053 (n.s)
B) Multivariate analysis
Parameter Significance Partial eta-square
Elastase ,0.001 0.141
Leukocyte count ,0.01 0.080
MPO n.s
Correlation analysis (A) of systolic, diastolic and mean blood pressure with markers of neutrophil activation and inflammation (MPO, elastase, leukocyte count, granulocytic count, Interleukin-6, CRP).
Coefficients of correlation are shown. Correlations were calculated using a Pearson product-moment correlation coefficient if variables were interval-scaled and normally distributed (MPO, elastase,
leukocyte count, granulocytic count, Interleukin-6). Otherwise, rank correlation using Spearman’s coefficient was performed (CRP).
Significant correlations were included into a multivariate linear model including systolic, diastolic and mean blood pressure as dependent variables (B).
*5 p# 0.05, **5p# 0.01. BP systolic5 systolic blood pressure, BP diastolic5 diastolic blood pressure, BP mean5mean arterial blood pressure, MPO5Myeloperoxidase, CRP5 C-reactive protein.
www.nature.com/scientificreports
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N-terminal prohormone of brain natriuretic peptide (NT-proBNP; LOCI-Test,
Siemens) and interleukin-6 (antibody-ECLIA, Roche). The following data were
recorded from clinical routine laboratory tests performed at the clinical central
laboratory, University Hospital Hamburg: differential blood count, CRP, AST, ALT,
GGT, bilirubin and creatinine.
In vitro analysis of whole blood. EDTA-blood was collected from healthy human
subjects and incubated with levosimendan for 6 hours (500 ng/ml) at room
temperature. Samples were subsequently stimulated with 20 ml of HBSS10.25% BSA
(control), or 20 ml of 100 nMPMA (phorbol 12-myristate 13-acetate), or 1 mMfMLP
(N-formyl-Met-Leu-Phe). Stimulation was performed for 45 minutes at room
temperature. Plasma was collected through centrifugation (1000 x g, 10 minutes) and
stored at 280uC until further analysis.
Statistical analysis.All calculations weremade with SPSS 17.0 (Statistical Package for
Social Science, Chicago) and GraphPad Prism 6.01. Normal distribution tested by
Kolmogorov-Smirnov-Test led to pairwise testing with Students unpaired t-test.
Otherwise the Mann-Whitney rank sum test was performed. Linear mixed-model
regression was used formultiple comparisons, and post-hoc Fisher’s Least Significant
Difference (LSD) tests were performed. Differences between timepoints of
levosimendan administration (for MPO, for example) were calculated using a linear
mixed model with inclusion of intersubject effects and timepoint as repeated
measurements, the specific plasma marker as dependent variable, and post-hoc LSD
testing.
Correlations were calculated using a Pearson product-moment correlation coef-
ficient if variables were interval-scaled and normally distributed. Otherwise, rank
correlation using a Spearman’s coefficient was performed.
Multivariable testing was performed using a general linearmodel including systolic
and diastolic blood pressure as dependent variables, and all markers of inflammation
that were significantly correlated with blood pressure as factors or co-variates (out of
MPO, elastase, nitrite, leukocyte count, granulocyte count, CRP, interleukin-6). Inter-
subject effects were calculated via partial eta squared.
A p value of ,0.05 was considered statistically significant. Data are presented as
mean6 SEM or median6 interquartile range if data were not normally distributed
or not interval scaled.
Results
Patient Characteristics. Table 1 shows the baseline patient
characteristics. The mean age was 58.4 6 2.6 years, and 28% of
Table 3 | Association analysis of blood pressure and inflammatory markers, patients without heparin medication
A) Correlation analysis – coefficients of correlation shown
MPO Elastase Leukocyte count Granulocyte count Interleukin-6 Systolic/diastolic BP
BP systolic 0.089 (n.s.) 0.293** 0.285** 20.232* 20.282** 0.747**
BP diastolic 0.042 (n.s.) 0.219* 0.076 (n.s.) 20.247* 20.116 (n.s.) 0.747**
BP mean 0.076 (n.s.) 0.177 (n.s.) 0.123 (n.s.) 20.257* 20.206 (n.s.) 0.907**/0.957**
CRP
BP systolic 20.422**
BP diastolic 20.202 (n.s.)
BP mean 20.304**
B) Multivariate analysis
Parameter Significance Partial eta-square
Leukocyte count ,0.01 0.173
Elastase p 5 0.056 0.083
Granulocyte count n.s.
Interleukin-6 n.s.
CRP n.s.
Correlation analysis (A) of systolic, diastolic and mean blood pressure with markers of neutrophil activation and inflammation (MPO, elastase, leukocyte count, granulocytic count, Interleukin-6, CRP).
Coefficients of correlation are shown. Significant correlations were included into a multivariate linear model including systolic, diastolic and mean blood pressure as dependent variables (B).
for details see also Table 2.
*5 p# 0.05, **5p# 0.01. BP systolic5 systolic blood pressure, BP diastolic5 diastolic blood pressure, BP mean5mean arterial blood pressure, MPO5Myeloperoxidase, CRP5 C-reactive protein.
Table 4 | Association analysis of blood pressure and inflammatory markers, patients with heparin medication
A) Correlation analysis– coefficients of correlation shown
MPO Elastase Leukocyte count Granulocyte count Interleukin-6 Systolic/diastolic BP
BP systolic 0.138 (n.s.) 0.366** 0.075 (n.s.) 20.013 (n.s.) 0.482** 0.469**
BP diastolic 0.349* 0.522** 0.055 (n.s.) 20.058 (n.s.) 0.066 (n.s.) 0.469**
BP mean 0.279 (p 5 0.055) 0.530** 0.092 (n.s.) 20.54 (n.s.) 0.271 (n.s.) 0.815**/0.904**
CRP
BP systolic 0.480**
BP diastolic 0.230 (n.s.)
BP mean 0.432**
B) Multivariate analysis
Parameter Significance Partial eta-square
Interleukin-6 ,0.01 0.282
MPO ,0.05 0.160
Elastase n.s.
CRP n.s.
Correlation analysis (A) of systolic, diastolic and mean blood pressure with markers of neutrophil activation and inflammation (MPO, elastase, leukocyte count, granulocytic count, Interleukin-6, CRP).
Coefficients of correlations are shown. Significant correlations were included into a multivariate linear model including systolic, diastolic and mean blood pressure as dependent variables (B).
for details see also Table 2.
*5 p # 0.05, **5p # 0.01. RR syst 5 systolic blood pressure, RR diast 5 diastolic blood pressure, MPO 5Myeloperoxidase, CRP 5 C-reactive protein.
www.nature.com/scientificreports
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patients were suffering from ischemic heart disease. The mean
pulmonary wedge pressure was 20.3 6 3.9 mmHg, and 56% of
patients were in NYHA Class IV functional status.
Markers of leukocyte funct ion/PMN-act ivat ion and
degranulation. Levosimendan treatment led to significantly
decreased MPO levels at 6 hours (from baseline 252.1 6 31.1 to
215.02 6 27.96 pmol/l at 6 h, p , 0.05; figure 1 A) and
significantly increased levels over the next week (to 377.4 6
15.4 pmol/l, p , 0.05), while elastase levels were decreased at 6
and 24 h (from baseline 103.2 6 17.7 ng/ml to 81 6 12.1 ng/ml at
6 h and 66.76 5.7 ng/ml at 24 h, p, 0.05; figure 1 B), but showed
no significant change after 2 or 7 days. Mean plasma nitrite
concentration as a marker of NO-production20 was not different
for the first 2 days but did show a highly significant increase after
7 days (from baseline 14.26 1.1 mM to 82.36 11.7 mM at 7 days, p
, 0.01; figure 1 C).
Association analysis of blood pressure and inflammatorymarkers.
As we were specifically interested in the association between PMN
activation and vascular tone, we evaluated the correlations between
systolic, diastolic, and mean blood pressure, and nitrite levels and
markers of leukocyte activity (elastase, MPO, granulocyte count,
leukocyte count) as well as inflammation (CRP, interleukin-6) in
our patients (table 2A). Plasma MPO, elastase and leukocyte count
all showed significant correlations with systolic, diastolic or mean
blood pressure. Multivariate linear regression analysis with systolic,
diastolic and mean blood pressure as dependent variables revealed
that plasma elastase and leukocyte count contributed significantly to
the final model, with the highest partial eta for elastase (table 2B).
It has been previously reported that administration of heparin
significantly increases levels of plasma MPO in patients.
Mechanistically, this is due to competitivemobilisation ofMPO from
extracellular matrix proteins or endothelial cells by heparan sulfate-
based glycosaminoglycans8. However, we identified no significant
effect of heparin administration on plasma MPO or elastase levels
in our patient cohort at any time point. To evaluate whether the
amount of vessel-bound MPO contributes to blood pressure regu-
lation in heart failure patients, we performed the above correlation
and multivariate analyses by stratifying patients in groups with (n5
9) orwithout (n5 16) heparin therapy during levosimendan-admin-
istration (table 3 and 4). In patients without heparin administration,
only leukocyte count contributed to the final model of blood pres-
sure, while themodel of blood pressure regulation in heparin-treated
patients included interleukin-6 and MPO, but not elastase.
Ex vivo evaluation of PMN-activation and degranulation in whole
blood. To investigate the direct effects of levosimendan on PMN-
activation, we incubated whole blood ex vivo with levosimendan at a
concentration of 500 ng/ml. Levosimendan alone did not have a
direct effect on MPO release from leukocytes in whole blood, but
after PMN-activation via fMLP/PMA, levosimendan significantly
decreased MPO-release vs. no levosimendan (8.2 6 1.4-fold
change vs. 6 6 0.9-fold change; Figure 2 A-B).
Figure 2 | Ex vivo effects of Levosimendan on MPO release in whole blood. Whole blood was taken from healthy controls and subsequently
incubated with 500 ng/ml Levosimendan for 6 hours at room temperature. If indicated, samples were stimulated with 20 ml of 100 nM PMA (phorbol
12-myristate 13-acetate) and 1 mM fMLP (N-formyl-Met-Leu-Phe) for 45 minutes on room temperature. (A) MPO-concentration after
Levosimendan incubation alone, n5 22. (B) Fold change ofMPO-concentration of stimulated (fMLP/PMA) over non-stimulated cells with and without
Levosimendan incubation, n 5 10. * 5 p # 0.05, **5p # 0.01 versus other group. Level of significance was determined using a Student’s T - test.
www.nature.com/scientificreports
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Markers of inflammation and heart failure.While leukocyte count
did not vary over the week-long time course (Fig. 3A), there was a
significant drop in relative PMN levels at 6 hours after levosimendan
application (64.78 6 2.37% vs. 68.17 6 2.22% at baseline, Fig. 3B.
Serum levels of CRP showed a significant decrease at 24 h (10.26 2.4
vs. 8.55 6 1.4 mg/dl, Fig. 3C). Interleukin-6 plasma levels were
significantly elevated in the first 24 h after levosimendan treatment
and decreased over the time course (Fig. 3D). NT-proBNP decreased
from 6907.9 6 1142.0 pg/ml to 3772.5 6 634.4 pg/ml, and patient
body weight dropped from 90.26 3.6 kg to 82.36 3.2 kg over the 7
days (Fig. 4A and B).
While severe hypotension is considered a known complication
necessitating stoppage of levosimendan-treatment, this did not occur
in any of our patients, although in 2 patients inotropic therapy was
escalated and further data were excluded. Nevertheless, we could show
statistically significant decreases in systolic, diastolic and mean blood
pressure in patients treated with levosimendan (Fig. 4 C and D).
Discussion
In this prospective, observational study of 25 patients with severe
heart failure, levosimendan-treatment reduced markers of cardiac
decompensation, like body weight or NTpro-BNP as previously
described21. Intriguingly, neutrophil elastase and MPO plasma con-
centrations (markers of neutrophil activation) were decreased 24 h
after treatment with levosimendan. Ex vivo incubation of EDTA-
blood with levosimendan decreased MPO release after PMN-stimu-
lation. Additionally, there was a significant correlation between neu-
trophil elastase and systolic, diastolic as well as mean blood pressure
over the complete time course, MPO correlated significantly with
diastolic blood pressure. In a multivariate linear model, elastase
remained a contributor to a model including systolic, diastolic and
mean blood pressure as dependent variables. A similar contribution
could be shown for MPO, but only in heparin-treated patients, sug-
gesting a more significant role for endothelial-bound MPO than for
circulating MPO or circulating elastase with respect to blood pres-
sure correlation. Plasma nitrite levels as a surrogate for overall NO-
bioavailability were significantly increased 1 week after treatment
with levosimendan.
While levosimendan has been shown to have anti-oxidative, anti-
inflammatory and anti-apoptotic effects, its immunmodulatory
effects are not completely understood and may be an important
mechanism to improve abnormal neurohormonal responses in heart
failure22–24. A recent study by Hasslacher et al.25 has shown that
levosimendan inhibits the release of reactive oxygen species from
stimulated PMNs in vitro and from PMNs derived from heart failure
patients. Our study demonstrates that levosimendan incubation of
whole blood decreases MPO release after stimulation ex vivo, under-
lining the immunmodulatory effects of levosimendan. Additionally,
our ex vivo data imply a systemic effect of levosimendan on PMN
activation with lower levels of MPO 24 hours after treatment. This is
Figure 3 | Effects of Levosimendan onmarkers of inflammation in plasma.Assessment of plasmamarkers at each specific time point after levosimendan
application (hours) for (A) leukocyte concentration, (B) relative granulocyte count, (C) CRP-concentration, (D) Interleukin-6 concentration. Data
displayed are for all available 25 patients (0–24 hours), 19 patients (48 hours) and 18 patients (168 hours). *5 p# 0.05, **5p# 0.01 versus timepoint
0 hours. Level of significance was determined using a mixed linear model with posthoc LSD test.
www.nature.com/scientificreports
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in agreement with published data showing improved endothelial
function 24 hours after levosimendan treatment18, as leukocyte
activation and especially MPO activity can significantly impair
endothelial function8. Avgeropoulou and colleagues have found a
decrease in MDA, a marker of oxidative stress, at day 5 after levosi-
mendan treatment26, which supports our hypothesis of diminished
PMN degranulation and MPO activity after levosimendan treat-
ment, as MPO activity and MDA-levels usually correlate well27.
Further, in a placebo-controlled study in patients with severe heart
failure, Parissis and colleagues19 reported a significant increase in
markers of oxidative and nitrosative stress like MDA, nitrotyrosine
and protein carbonyls in the placebo group 48 hours after treatment
which did not occur in the levosimendan-treated group. This indi-
cates an anti-oxidative and anti-nitrosative effect of levosimendan, as
nitrotyrosine formation is downstream of MPO activity, with MPO-
generated nitrogen dioxide (NO2N) strongly contributing to nitrotyr-
Figure 4 | Effects of Levosimendan on heart failure markers and blood pressure in plasma. Assessment of plasma markers at each specific time point
after levosimendan application (hours) for (A) NT-proBNP (B) body weight, (C) systolic blood pressure, (D) diastolic blood pressure, (E)mean arterial
pressure. Data displayed are for all available 25 patients (0–24 hours), 19 patients (48 hours) and 18 patients (168 hours). *5 p# 0.05, **5p# 0.01
versus timepoint 0 hours. Level of significance was determined using a mixed linear model with posthoc LSD test.
www.nature.com/scientificreports
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osine formation7. These anti-inflammatory effects might in part be
explained by inhibition of MPO-release by levosimendan.
Most intriguingly, we identified a significant increase in MPO
levels at 7 days after levosimendan. This augmentation in MPO-
concentration occurred without a coincident increase in elastase
levels, indicating an underlying mechanism separate from PMN
degranulation. Several other explanations may apply. Former studies
have shown that a release of MPO from the endothelial glycocalyx is
possible, allowing the vessel wall to achieve higher NO-availability
and improved flow-mediated dilation8. The significant increase in
plasma nitrite, a sustainable marker of NO production by eNOS,
which occurred simultaneously with the increase in MPO, might
suggest that MPO was released from the endothelium, increasing
NO-bioavailability. More detailed studies are needed to explore this,
as we can only speculate that increases in MPO and nitrite plasma
levels are causally connected.
Increased nitrite plasma levels can also be amarker of macrophage
activation28, but we did not find elevated markers of inflammation
corresponding with nitrite levels. In fact, there were no significant
increases in interleukin-6, granulocyte count, leukocyte count or
CRP at 1 week after levosimendan treatment.
In porcine endothelial cells, levosimendan causes an increase in
NO-concentration by activation of eNOS via MAP-kinases like p38,
AKT and ERK29. However, we would expect that effects of levosi-
mendan on endothelial cells and eNOS would be more pronounced
at earlier timepoints, leaving the increase of nitrite levels in our
patient group unexplained.
Adamopoulos et al. showed anti-inflammatory effects of levosi-
mendan on day 3 after levosimendan in heart failure patients with
regard to TNF-alpha, interleukin-6, soluble Fas and soluble Fas-
ligand24. While we cannot provide information on TNF-alpha or
Fas, we did measure IL-6. In our patient population, which had
distinctly higher IL-6 and NT-proBNP levels than in
Adamopoulus et al., we found an increase in IL-6 concentration at
6, 24 and 48 hours after the beginning of levosimendan treatment,
but then a subsequent decline vs. baseline with a significant decrease
from 12 h to 7 d after treatment. This decline over days has been
previously observed in 29 patients with severe heart failure at day 5
after levosimendan treatment26. Ischemia and subsequent reperfu-
sion have been shown to increase IL-6 release from rat cardiomyo-
cytes30. Therefore our IL-6 peakmight be at least in part explained by
early levosimendan-induced hemodynamic improvements.
Furthermore, in our population, the initial increase in IL-6 is not
reflected by CRP curve progression, even though both markers posi-
tively correlate over all patients and the complete time course (r 5
0.384, p , 0.01). Intriguingly, there was a clear opposition in IL-6
and CRP-curve shape during the study period. This was unexpected,
as IL-6 is considered a main inducer for acute-phase-protein pro-
duction, which includes CRP. It has been shown before that both
markers are elevated during acute cardiac decompensation31, and
subsequently decrease with improvement of that condition, but
may have different kinetics32. Therefore, a therapeutic approach to
HF with levosimendan might resemble a condition in which IL-6 is
increased but CRP will not necessarily follow.
We additionally evaluated parameters of PMN activation and
inflammation that were associated with blood pressure in a multi-
variate regression model. While our analysis does not provide causal
insights, we utilized systolic, diastolic and mean blood pressure as an
indirect estimate of endothelium-dependent vasoconstriction, as
blood pressure correlates with endothelial function33–35 and mean
arterial pressure is an indicator for general vascular resistance and
perfusion pressure36,37. Therefore, it is of importance that elastase
and MPO contributed to final models of blood pressure.
Intriguingly, the contribution of MPO exceeded the contribution
of elastase to the final model in the heparin-treated patients, as elas-
tase was not significantly associated with blood pressure in these
patients. This is coincident with the observation of an increased
correlation coefficient between MPO and diastolic blood pressure
in patients with heparin administration compared to no heparin or
all patients (heparin: R5 0.349, p, 0.05; no heparin: 0.042, n.s.; all
patients: 0.179, p , 0.05). The administration of heparin may have
mobilized a portion of endothelial-immobilised MPO, which could
then be quantified, and which otherwise would have remained
unmeasured and ‘hidden’ on the endothelium.
Since we found that endothelial-boundMPO and PMN activation
are significantly correlated with blood pressure regulation in HF
patients treated with levosimendan, this implies a direct influence
of blood pressure regulation on leukocyte and especially PMNactiva-
tion and endothelial MPO deposition. On the other hand, given the
inhibitory effect of levosimendan on MPO-release in whole blood ex
vivo, and after 24 hours in vivo, inhibition of PMN function through
levosimendan might contribute to better endothelial-dependent vas-
cular function with more NO bioavailability and lower blood pres-
sure. A direct effect on PMNs would imply less MPO deposition on
the endothelial layer38 and former work from our lab has already
shown that MPO-activity in PMNs is inversely correlated with
flow-mediated dilation, with MPO administration impairing myo-
cardial perfusion.
We acknowledge that our work has certain limitations. The imple-
mentation of a randomized control group (randomization of
levosimendan application vs. no levosimendan application) raised
ethical concerns. Therefore we do not have a sufficient untreated
control group, and can only compare changes over the time course
of levosimendan application, but not to patients that have improved
without levosimendan treatment. Further, the correlation and
regression analyses we performed do not necessitate causal connec-
tion, and in general show moderate strength.
Nevertheless, our data suggest that levosimendan has inhibitory
effects on MPO release which might be beneficial for vascular
endothelial function, contributing to blood pressure regulation in
heart failure patients. Given the general state of neurohormonal
activation which accompanies acute heart failure decompensation,
the direct effects of levosimendan on MPO release and PMN activa-
tion have likely been under-recognised.
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